Clinical trial
Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment…
NCT00149214 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00149214 |
|---|---|
| Title | Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens |
| Official title | A Randomized Phase 2 Trial of Doxorubicin Plus Pemetrexed Followed by Docetaxel, Versus Doxorubicin Plus Cyclophosphamide Followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed, cyclophosphamide, doxorubicin, docetaxel |
| Enrollment | 257 |
| Start date | Sep 1, 2005 |
| Primary completion | Feb 1, 2008 |
| Completion | Mar 1, 2011 |
| First posted | Sep 8, 2005 |
| Last update posted | Mar 21, 2012 |
| Countries | Germany, Italy, Russia, Spain |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: